StockData

Yarrow Bioscience, Inc. (YARW) stock

YARWNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 11/30105% above fair value
$14.35+0.14 (+0.99%)

Close on Nov 18, 2026Market cap $38.31MP/E –Yield –

Yarrow Bioscience operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Yarrow Bioscience's operating income for the twelve months ending Jun 30, 2025 was -$42.60M. For fiscal 2025 it was -$29.75M. The highest annual figure on record is -$4.61M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.75M–
FY2024Dec 31, 2024-$43.64M–
FY2023Dec 31, 2023-$29.26M–
FY2022Dec 31, 2022-$34.30M–
FY2021Dec 31, 2021-$38.91M–
FY2020Dec 31, 2020-$252.55M–
FY2019Dec 31, 2019-$95.87M–
FY2018Dec 31, 2018-$74.89M–
FY2017Dec 31, 2017-$29.59M–
FY2016Dec 31, 2016-$14.33M–
FY2015Dec 31, 2015-$4.61M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.10M–
Q1 FY2026Mar 31, 2026-$3.82M–
Q2 FY2025Jun 30, 2025-$7.54M–
Q1 FY2025Mar 31, 2025-$9.20M–
Q4 FY2024Dec 31, 2024-$12.77M–
Q3 FY2024Sep 30, 2024-$13.09M–
Q2 FY2024Jun 30, 2024-$10.40M–
Q1 FY2024Mar 31, 2024-$7.38M–
Q4 FY2023Dec 31, 2023-$6.83M–
Q3 FY2023Sep 30, 2023-$6.23M–
Q2 FY2023Jun 30, 2023-$10.32M–
Q1 FY2023Mar 31, 2023-$5.88M–
Q4 FY2022Dec 31, 2022-$7.98M–
Q3 FY2022Sep 30, 2022-$9.33M–
Q2 FY2022Jun 30, 2022-$8.29M–
Q1 FY2022Mar 31, 2022-$8.69M–
Q4 FY2021Dec 31, 2021-$8.85M–
Q3 FY2021Sep 30, 2021-$10.77M–
Q2 FY2021Jun 30, 2021-$9.54M–
Q1 FY2021Mar 31, 2021-$9.76M–
Q4 FY2020Dec 31, 2020-$21.99M–
Q3 FY2020Sep 30, 2020-$23.49M–
Q2 FY2020Jun 30, 2020-$167.18M–
Q1 FY2020Mar 31, 2020-$39.89M–
Q4 FY2019Dec 31, 2019-$37.43M–
Q3 FY2019Sep 30, 2019-$23.20M–
Q2 FY2019Jun 30, 2019-$19.36M–
Q1 FY2019Mar 31, 2019-$15.88M–
Q4 FY2018Dec 31, 2018-$38.80M–
Q3 FY2018Sep 30, 2018-$13.70M–
Q2 FY2018Jun 30, 2018-$9.17M–
Q1 FY2018Mar 31, 2018-$13.22M–
Q4 FY2017Dec 31, 2017-$9.48M–
Q3 FY2017Sep 30, 2017-$8.34M–
Q2 FY2017Jun 30, 2017-$6.23M–
Q1 FY2017Mar 31, 2017-$5.56M–

More Yarrow Bioscience figures

See a number that looks wrong?